Clinical trials: Hematological Malignancies
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients
This phase II trial studies fentanyl buccal tablet or morphine to see how well it works compared to a placebo in controlling shortness of breath during or after physical activity in cancer patients.
- Trial name
- NCT04188418
- Testing
- Fentanyl Citrate Buccal Tablet, Morphine, Physical Performance Testing
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Bronchiolitis Obliterans Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
This observational trial studies whether respiratory viruses are the cause of lung disease (bronchiolitis obliterans syndrome [BOS] or graft-versus-host disease of the lung) and changes in lung function in patients who have…
- Trial name
- NCT05250037
- Testing
- Home spirometry, Biospecimen Collection, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 261 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancy, Solid Tumor
Voraxaze for Delayed Methotrexate Clearance
Primary Objectives: 1. To evaluate the efficacy of Glucarpidase (Voraxaze) in increasing the rate of methotrexate (MTX) clearance following high dose MTX treatment in patients with a delayed MTX clearance. 2.
- Trial name
- NCT00424645
- Testing
- Voraxaze (Glucarpidase)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML)
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Pilot Study Evaluating the Safety and Efficacy of a Co-Transplantation of NiCord®, a UCB-derived ex Vivo Expanded Population of Stem and Progenitor Cells with a Second, Unmanipulated CBU in Patients with Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma
- Trial name
- NCT01221857
- Testing
- NiCord®
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gamida Cell ltd
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT00807677
- Testing
- TAK-901
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Tumor Lysis Syndrome
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect…
- Trial name
- FLORET (NCT03605212)
- Testing
- Febuxostat
- Where
- 17 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 30 people
- Sponsor
- Menarini Group
Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission
Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies
Determine the safety and tolerability of POL6326 when used as a single mobilization agent.
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia (CML), Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission
- Trial name
- NCT01413568
- Testing
- POL6326, Leukapheresis, PBSC Transplant
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Polyphor Ltd.
Hematological Malignancies
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
This observational study is proposed to observe the effect of high-dose, post-transplantation cyclophosphamide after a T cell-replete, HLA-matched PBSC graft from an HLA-identical or mismatched donor.
- Trial name
- NCT02300571
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Lymphoma, Leukemia
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma
- Trial name
- NCT00621244
- Testing
- LBH589
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Trial of Chemotherapy Plus Intravenous Vitamin C in Patients With Advanced Cancer for Whom Chemotherapy Alone is Only Marginally Effective
Concurrent administration of intravenous vitamin C (ascorbic acid, 1.5 g/kg, infused two or three times weekly) together with certain cytotoxic chemotherapy regimens could prove to be an effective treatment for some patients with…
- Trial name
- NCT01050621
- Testing
- vitamin C (ascorbic acid)
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Jewish General Hospital
Polycythemia Vera
Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera
The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and…
- Trial name
- PEGINVERA (NCT01193699)
- Testing
- PEG-P-INF alpha-2b (P1101)
- Where
- 6 sites in Austria
- Volunteers
- 24 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Breast Cancer, Kidney Cancer
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
RATIONALE: Giving low doses of chemotherapy and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Breast Cancer, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00365287
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Volunteers
- 148 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Blood Cancer, Lymphoma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function.
- Conditions
- Blood Cancer, Lymphoma, Leukemia, Myeloma
- Trial name
- NCT07052916
- Testing
- Music Therapy/MT, Therapist-Attention Music Education/TAME Control
- Where
- 7 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematologic Malignancies
Anidulafungin in Patients With Hematologic Malignancies
Study objectives To evaluate the safety of the echinocandin anidulafungin for prophylaxis or treatment of invasive fungal infections (IFI) in hematologic patients.
- Trial name
- ECALTA (NCT01053884)
- Testing
- Anidulafungin
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Elisabethinen Hospital
Polycythemia Vera
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Clopidogrel (Plavix) and aspirin are two antithrombotic agents (blood thinners) commonly used in patients with previous thrombotic events (stroke or heart attack). Thrombosis is the formation of a blood clot in a blood vessel.
- Trial name
- ISCLAP (NCT00940784)
- Testing
- Clopidogrel (Plavix), Aspirin
- Sponsor
- Ronald Hoffman
AML, ALL
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic…
- Conditions
- AML, ALL, MDS, MPD Withou Myelofibrosis
- Trial name
- NCT04644016
- Testing
- Clofarabine, Fludarabine, Busulfan
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced B-cell Lymphoid Malignancies
Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
This is a Phase 0/1 open-label, non-randomized, biomarker and pharmacodynamic study in patients with advanced B-cell lymphoid malignancies, including B-cell chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)…
- Trial name
- NCT01888952
- Testing
- Prednisone, Roflumilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Anand B. Karnad
Chronic Lymphocytic Leukemia, Multiple Myeloma
Financial Difficulty in Patients With Blood Cancer
This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
- Trial name
- NCT05212233
- Where
- 7 sites in United States
- Volunteers
- 218 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematologic Malignancies
Infusional C-myb ASODN in Advanced Hematologic Malignancies
The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.
- Trial name
- UPCC 04701 (NCT00780052)
- Testing
- c-myb AS ODN
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.